489 related articles for article (PubMed ID: 22644789)
1. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.
Gibbons LE; Carle AC; Mackin RS; Harvey D; Mukherjee S; Insel P; Curtis SM; Mungas D; Crane PK;
Brain Imaging Behav; 2012 Dec; 6(4):517-27. PubMed ID: 22644789
[TBL] [Abstract][Full Text] [Related]
2. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.
Skinner J; Carvalho JO; Potter GG; Thames A; Zelinski E; Crane PK; Gibbons LE;
Brain Imaging Behav; 2012 Dec; 6(4):489-501. PubMed ID: 22614326
[TBL] [Abstract][Full Text] [Related]
3. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Crane PK; Carle A; Gibbons LE; Insel P; Mackin RS; Gross A; Jones RN; Mukherjee S; Curtis SM; Harvey D; Weiner M; Mungas D;
Brain Imaging Behav; 2012 Dec; 6(4):502-16. PubMed ID: 22782295
[TBL] [Abstract][Full Text] [Related]
4. Confirmatory factor analysis of the ADNI Neuropsychological Battery.
Park LQ; Gross AL; McLaren DG; Pa J; Johnson JK; Mitchell M; Manly JJ;
Brain Imaging Behav; 2012 Dec; 6(4):528-39. PubMed ID: 22777078
[TBL] [Abstract][Full Text] [Related]
5. Cortical signatures of cognition and their relationship to Alzheimer's disease.
Gross AL; Manly JJ; Pa J; Johnson JK; Park LQ; Mitchell MB; Melrose RJ; Inouye SK; McLaren DG;
Brain Imaging Behav; 2012 Dec; 6(4):584-98. PubMed ID: 22718430
[TBL] [Abstract][Full Text] [Related]
6. Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease.
Nho K; Risacher SL; Crane PK; DeCarli C; Glymour MM; Habeck C; Kim S; Lee GJ; Mormino E; Mukherjee S; Shen L; West JD; Saykin AJ;
Brain Imaging Behav; 2012 Dec; 6(4):551-67. PubMed ID: 23070747
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment.
Johnson JK; Gross AL; Pa J; McLaren DG; Park LQ; Manly JJ;
Brain Imaging Behav; 2012 Dec; 6(4):540-50. PubMed ID: 22562439
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF).
Staffaroni AM; Asken BM; Casaletto KB; Fonseca C; You M; Rosen HJ; Boxer AL; Elahi FM; Kornak J; Mungas D; Kramer JH
Alzheimers Dement; 2021 Apr; 17(4):574-583. PubMed ID: 33215852
[TBL] [Abstract][Full Text] [Related]
9. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
10. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
van Loenhoud AC; van der Flier WM; Wink AM; Dicks E; Groot C; Twisk J; Barkhof F; Scheltens P; Ossenkoppele R;
Neurology; 2019 Jul; 93(4):e334-e346. PubMed ID: 31266904
[TBL] [Abstract][Full Text] [Related]
11. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
[TBL] [Abstract][Full Text] [Related]
12. Independent value added by diffusion MRI for prediction of cognitive function in older adults.
Scott JA; Tosun D; Braskie MN; Maillard P; Thompson PM; Weiner M; DeCarli C; Carmichael OT;
Neuroimage Clin; 2017; 14():166-173. PubMed ID: 28180075
[TBL] [Abstract][Full Text] [Related]
13. Mild to moderate decrease in eGFR and cognitive decline in older adults.
Grasing M; Kennedy K; Sarnak MJ; Burns JM; Gupta A
Nephrol Dial Transplant; 2022 Jul; 37(8):1499-1506. PubMed ID: 34289074
[TBL] [Abstract][Full Text] [Related]
14. Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data.
Ye J; Farnum M; Yang E; Verbeeck R; Lobanov V; Raghavan N; Novak G; DiBernardo A; Narayan VA;
BMC Neurol; 2012 Jun; 12():46. PubMed ID: 22731740
[TBL] [Abstract][Full Text] [Related]
15. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
17. Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes.
Asken BM; Thomas KR; Lee A; Davis JD; Malloy PF; Salloway SP; Correia S
J Int Neuropsychol Soc; 2020 May; 26(5):464-479. PubMed ID: 31822312
[TBL] [Abstract][Full Text] [Related]
18. Mild-moderate CKD is not associated with cognitive impairment in older adults in the Alzheimer's Disease Neuroimaging Initiative cohort.
Gupta A; Kennedy K; Perales-Puchalt J; Drew D; Beddhu S; Sarnak M; Burns J;
PLoS One; 2020; 15(10):e0239871. PubMed ID: 33036021
[TBL] [Abstract][Full Text] [Related]
19. TNF receptors are associated with tau pathology and conversion to Alzheimer's dementia in subjects with mild cognitive impairment.
Zhao A; Li Y; Deng Y;
Neurosci Lett; 2020 Nov; 738():135392. PubMed ID: 32947003
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.
Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S
JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
